tirzepatide/mounjaro Mounjaro (tirzepatide) for the Treatment of Type 2 Diabetes, USA GIP and GLP Mounjaro (Tirzepatide) Injection 7.5 mg/0.5

It was noted that belching complaints were more common among patients receiving liraglutide or semaglutide, whereas such an increase was not observed with exenatide or tirzepatide

Many patients regain some or much of the lost weight if: diet changes are not sustained physical activity is low emotional eating returns underlying insulin resistance remains the medicine is stopped too early This is especially common if the medicine was doing most of the work and lifestyle measures were not strong enough in the background

14 1

There should always be a minimum of 3 days between each Mounjaro dose

The rationale behind cyclical dosing connects directly to epitalon's mechanism of action

Not three weeks and a couple of extra days